Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biovet JSC's enterprise value is лв0.00 Mil.
Biovet JSC's EBITDA for the trailing twelve months (TTM) ended in Dec. 2016 was лв19.74 Mil. Therefore, Biovet JSC's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Biovet JSC's EV-to-EBITDA or its related term are showing as below:
LTS:0III'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4 Med: 7.4 Max: 27
Current: 6.73
During the past 8 years, the highest EV-to-EBITDA of Biovet JSC was 27.00. The lowest was 5.40. And the median was 7.40.
LTS:0III's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 13.325
vs LTS:0III: 6.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biovet JSC's share price for today is лв0.00.
Biovet JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biovet JSC's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0III vs ADMP, AGRX, BUDZ: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biovet JSC's EV-to-EBITDA falls into.
Biovet JSC's current Enterprise Value is лв0.00 Mil.
Biovet JSC's EBITDA for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв19.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biovet JSC (LTS:0III) has a EV-to-EBITDA of 0.00 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biovet JSC. Over the past decade, Biovet JSC's EV-to-EBITDA has ranged from 5.40 to 27.00.
Is Biovet JSC's EV-to-EBITDA too high?
Biovet JSC's current EV-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 5.40 to a high of 27.00.
How does Biovet JSC's EV-to-EBITDA compare to ADMP and AGRX?
Biovet JSC's EV-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 13.33. Historically, Biovet JSC's own EV-to-EBITDA has ranged from 5.40 to 27.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biovet JSC. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current EV-to-EBITDA is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
